問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

Taichung Veterans General Hospital

List

1449Cases

2011-07-01 - 2016-03-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Terminated7Sites

2012-05-01 - 2014-05-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites

2012-08-01 - 2014-06-30

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

2013-02-01 - 2016-12-31

Phase III

A Phase 3 Randomized, Double Blind, Regional Multi-National Evaluation of Daclatasvir in Combination with Peg-Interferon Alfa-2a and Ribavirin in Treatment-Naïve Subjects with Chronic Hepatitis C Genotypes 1 and 4

  • Condition/Disease

    Hepatitis C virus

  • Test Drug

    BMS-790052

Participate Sites
10Sites

Terminated10Sites

2013-05-01 - 2017-12-31

Phase III

A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of BMS-188667 (Abatacept) or Placebo on a Background of Mycophenolate Mofetil (MMF) and Corticosteroids in Subjects with Active Class III or IV Lupus Nephritis

  • Condition/Disease

    Active Class III or IV Lupus Nephritis

  • Test Drug

    Abatacept (BMS-188667)

Participate Sites
5Sites

Terminated4Sites

Study ended1Sites

2018-02-08 - 2018-02-08

Phase III

A Randomized, Global, Open-label Study of Nivolumab in Combination With BMS-986205 vs Standard of Care EXTREME Regimen in First-line Recurrent/Metastatic Squamous Cell Carcinoma of Head and Neck

  • Condition/Disease

    Recurrent/Metastatic Squamous Cell Carcinoma of Head and Neck

  • Test Drug

    BMS-986205/Nivolumab

Participate Sites
3Sites

Terminated3Sites

2015-12-01 - 2016-12-23

Phase III

An Open-label, Randomized, Phase 3 Study of Nivolumab or Chemotherapy in Subjects with Relapsed Small-cell Lung Cancer after Platinum-based Fist Line Chemotherapy

  • Condition/Disease

    Small-cell Lung Cancer

  • Test Drug

    Nivolumab

Participate Sites
4Sites

Terminated3Sites

夏德椿
China Medical University Hospital-Taipei

未分科

2017-05-01 - 2023-10-30

Phase III

Open-Label, Randomized Trial of Nivolumab (BMS-936558) plus Pemetrexed/Platinum or Nivolumab plus Ipilimumab (BMS-734016) vs Pemetrexed plus Platinum in Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC) Subjects with Epidermal Growth Factor Receptor (EGFR) Mutation, T790M Negative Who Failed 1L EGFR Tyrosine Kinase Inhibitor Therapy

  • Condition/Disease

    NSCLC

  • Test Drug

    Nivolumab (BMS-936558),Ipilimumab (BMS-734016)

Participate Sites
16Sites

Terminated14Sites

黃煦晴
Taipei Veterans General Hospital

楊政達
Linkou Chang Gung Medical Foundation

Division of Thoracic Medicine

2014-07-01 - 2015-12-31

Phase III

A Phase 3 Study of a daclatasvir/asunaprevir/BMS-791325 Fixed Dose Combination (FDC) in Subjects with Chronic Hepatitis C Genotype 1 (UNITY 4)

  • Condition/Disease

    Chronic Hepatitis C Genotype 1

  • Test Drug

    Daclatasvir/Asunaprevir/BMS-791325; Film coated tablet; 30 mg/200 mg/75 mg (as the free base)

Participate Sites
8Sites

Terminated7Sites

Study ended1Sites

彭成元
China Medical University Hospital

Digestive System Department

2019-11-30 - 2024-07-31

Phase III

A Randomized, Multi-center, Phase 3 Study of Nivolumab in Combination With Ipilimumab Compared to Sorafenib or Lenvatinib as First-Line Treatment in Participants With Advanced Hepatocellular Carcinoma

  • Condition/Disease

    Advanced Hepatocellular Carcinoma

  • Test Drug

    OPDIVO (nivolumab) Injection 10mg/mLOPDIVO (nivolumab) Injection 10mg/mLYERVOY (ipilimumab) Injection 5mg/mLYERVOY (ipilimumab) Injection 5mg/mL

Participate Sites
9Sites

Recruiting9Sites

1 139 140 141 142 143 145
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB